New gefitinib crystal form and its preparation method based on supercritical anti-solvent technology

South China University of Technology SCUT 2019. New gefitinib crystal form and its preparation method based on supercritical anti-solvent technology. CN106083739B. [Patent].

Full text not available from this repository.

Abstract

The invention discloses a new crystal form of gefitinib and a preparation method based on supercritical anti-solvent technology. The new crystal form of gefitinib is the β crystal form, and the β crystal form has the strongest characteristic peak at the position of 2θ angle of 6.7 on the XRPD spectrum; the position of the 2θ angle of about 6.7 and 13.0 on the XRPD spectrum has the main characteristic peaks, so The relative intensity of the main characteristic peaks is greater than 20%; there are characteristic peaks at the 2θ angles of 14.0, 19.7, 26.1, 32.8, 38.8, 40.5, 46.5 on the XRPD spectrum, and the relative intensity of the characteristic peaks is not greater than 5%. The preparation method based on the supercritical anti-solvent technology has the advantages of simple process, mild conditions and good reproducibility, and the obtained gefitinib crystal form β has a smaller particle size, a narrow particle size distribution and higher solubility.

Item Type:	Patent
Date Type:	Publication
Status:	Published
Schools:	Schools > Engineering
Last Modified:	28 Feb 2025 15:49
URI:	https://orca.cardiff.ac.uk/id/eprint/176437

Actions (repository staff only)

Edit Item